TRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for severe hypertriglyceridemia (sHTG)

Impact · against what's priced in

The CHMP recommendation for Tryngolza is a positive regulatory milestone, but it provides minimal catalyst for IONS as the market has already baked in the drug's approval for severe hypertriglyceridemia. The core valuation driver remains the commercial uptake of the drug and upcoming clinical trials, rather than the binary event of regulatory approval.

IONS+0.05

Already priced in

The price assumes

The recent FDA approval of Zanvastro for Alexander disease and Tryngolza for severe hypertriglyceridemia, both now factored in as baseline assets.